Geoffrey Rogers, MD
Allergy & Immunology · Elkhart, INNPI 1265437255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 353 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,214 and has fallen 63.4% since, to $445 in 2025.
Across 353 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$812
- AstraZeneca$572
- GSK$518
- AbbVie$475
- Amgen$452
- Pfizer$411
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,496100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,519 in reported general payments places this provider in the 55th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 378 | $104,399 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $84,693 |
| JanuviaSitagliptin Phosphate | 119 | $82,027 |
| AustedoDeutetrabenazine | 32 | $77,361 |
| Austedo XrDeutetrabenazine | 15 | $68,268 |
| JardianceEmpagliflozin | 59 | $50,921 |
| OzempicSemaglutide | 31 | $41,966 |
| XareltoRivaroxaban | 120 | $35,076 |
| Spiriva RespimatTiotropium Bromide | 46 | $35,063 |
| FarxigaDapagliflozin Propanediol | 60 | $30,095 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $24,596 |
| MounjaroTirzepatide | 15 | $22,217 |
| TradjentaLinagliptin | 143 | $20,975 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $20,657 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $18,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $37 | $145,62947 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta, Anoro Ellipta | $518 | $138,338212 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $165 | $106,959248 claims |
| PfizerEliquis | $411 | $104,399378 claims |
| MerckJanuvia, Janumet | $224 | $99,039138 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma, Symbicort | $572 | $67,096113 claims |
| Novo NordiskOzempic | $812 | $41,96631 claims |
| Lilly USA, LLCMounjaro, Trulicity | $112 | $40,63836 claims |
| Johnson & JohnsonXarelto | $119 | $35,076120 claims |
| AbbVieLinzess, Creon | $475 | $20,16330 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $306 | $16,99829 claims |
| NovartisEntresto | $214 | $12,88539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Elkhart
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Majed KoleilatEvansville$122K
- Pinkus GoldbergIndianapolis$89K
- Douglas NeeldFort Wayne$77K
- Pooja PatelMerrillville$55K
- Mitchell SmithGreenwood$33K
- Ketan ShethLafayette$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.